Patricia A. Young, MD

Patricia Young, MD

Assistant Professor, Department of Medicine, Hematology/Oncology





Hematology/Oncology, University of California, Los Angeles, 2016


Internal Medicine, Cedars-Sinai Medical Center, 2010


MS, University of California, Los Angeles, 2016
MD, Drexel University College of Medicine, 2009
BS, University of California, Los Angeles, CA, 2004


Internal Medicine, Cedars-Sinai Medical Center, 2012

Board Certifications

Hematology, American Board of Internal Medicine, 2016
Medical Oncology, American Board of Internal Medicine, 2015

Contact Information

Scientific Interests

Dr. Patricia Young specializes in hematology and medical oncology with an emphasis in clinical and translational research. She is a member of the UCLA Bone Marrow Transplant and Cellular Therapy team, and conducts clinical trials in the Hematologic Malignancies Program and the Lymphoma Program. She has also worked with the UCLA Thoracic Oncology Program studying the effects of estrogens in non-small cell lung cancer.

Highlighted Publications

Young P, Kim B, Malin JL. Preoperative breast MRI in early-stage breast cancer. Breast Cancer Research and Treatment, Oct; 135(3): 907-12, 2012. PMID 22923237

Young PA, Morrison SL, Timmerman JM. Antibody-Cytokine Fusion Proteins for Treatment of Cancer: Engineering Cytokines for Improved Efficacy and Safety. Seminars in Oncology Oct; 41(5): 623-36, 2014. PMID: 25440607

Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Parikh RJ, Patel R, Hu EH, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang H, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018. 123: p. 91-98. PMID: 30089602

Young PA, Yamada RE, Trinh DR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM. Activity of anti-CD19 CAR T cells against B cell lymphoma is enhanced by antibody-targeted interferon-alpha. Journal of Interferon & Cytokine Research, 2018 Jun;38(6):239-254. PMID: 29920129

Young PA, Gaut D, Kimaiyo DK, Grotts J, Chute JP, Schiller GJ, de Vos S, Eradat HA, Timmerman JM. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32229199